Business Standard

Unichem Labs surges 15% on ANDA nod from USFDA for Aripiprazole tablets

Aripiprazole tablets are indicated for Schizophrenia and Irritability associated with Autistic Disorder

Unichem Laboratories. Photo: UnichemLabs.com
Premium

Unichem Laboratories. Photo: UnichemLabs.com

SI Reporter Mumbai
Shares of Unichem Laboratories surged 15 per cent to Rs 257 on the BSE in Friday’s intra-day trade after the company announced that it has received ANDA approval for its Aripiprazole tablets USP from the United States Food and Drug Administration (USFDA).

Aripiprazole tablets are indicated for Schizophrenia and Irritability associated with Autistic Disorder. The product will be commercialized from Unichem’s Ghaziabad Plant, the company said.

“The company has received ANDA approval for its Aripiprazole tablets USP, 2 mg, 5 mg, 10 mg, 15 mg, 20 mg, and 30 mg from the United States Food and Drug Administration

What you get on BS Premium?

  • Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
  • Pick your 5 favourite companies, get a daily email with all news updates on them.
  • Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
  • Preferential invites to Business Standard events.
  • Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.
VIEW ALL FAQs

Need More Information - write to us at assist@bsmail.in